These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31563883)

  • 1. Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer.
    Goto Y; Thike AA; Ong CCH; Lim JX; Md Nasir ND; Li H; Koh VCY; Chen XY; Yeong JPS; Sasano H; Tan PH
    J Clin Pathol; 2020 Mar; 73(3):147-153. PubMed ID: 31563883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
    Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
    Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor status is highly conserved during tumor progression of breast cancer.
    Grogg A; Trippel M; Pfaltz K; Lädrach C; Droeser RA; Cihoric N; Salhia B; Zweifel M; Tapia C
    BMC Cancer; 2015 Nov; 15():872. PubMed ID: 26552477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis.
    Wang C; Pan B; Zhu H; Zhou Y; Mao F; Lin Y; Xu Q; Sun Q
    Oncotarget; 2016 Jul; 7(29):46482-46491. PubMed ID: 27374089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients.
    Govindan S; Siraganahalli Eswaraiah M; Basavaraj C; Adinarayan M; Sankaran S; Bakre M
    BMC Cancer; 2020 Aug; 20(1):745. PubMed ID: 32778063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer.
    Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
    Hum Pathol; 2016 Sep; 55():190-5. PubMed ID: 27184484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between androgen receptor status and prognosis in triple negative breast cancer.
    Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K
    J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
    Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
    Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
    Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
    Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
    Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
    J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.
    McNamara KM; Oguro S; Omata F; Kikuchi K; Guestini F; Suzuki K; Yang Y; Abe E; Hirakawa H; Brown KA; Takanori I; Ohuchi N; Sasano H
    Breast Cancer Res Treat; 2017 Jan; 161(2):213-227. PubMed ID: 27848152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis.
    Xu M; Yuan Y; Yan P; Jiang J; Ma P; Niu X; Ma S; Cai H; Yang K
    Clin Breast Cancer; 2020 Aug; 20(4):e385-e396. PubMed ID: 32139270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
    Guiu S; Mollevi C; Charon-Barra C; Boissière F; Crapez E; Chartron E; Lamy PJ; Gutowski M; Bourgier C; Romieu G; Simony-Lafontaine J; Jacot W
    Br J Cancer; 2018 Jul; 119(1):76-79. PubMed ID: 29880907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer.
    Lyalkin SA; Verevkina NO; Alekseyenko OO; Syvak LA
    Exp Oncol; 2020 Jun; 42(2):140-143. PubMed ID: 32602289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
    Ricciardi GR; Adamo B; Ieni A; Licata L; Cardia R; Ferraro G; Franchina T; Tuccari G; Adamo V
    PLoS One; 2015; 10(6):e0128368. PubMed ID: 26039245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
    Kim MC; Choi JE; Lee SJ; Bae YK
    Ann Surg Oncol; 2016 Oct; 23(11):3524-3530. PubMed ID: 27278204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer.
    Xu F; Xu K; Fan L; Li X; Liu Y; Yang F; Zhu C; Guan X
    Chin Med J (Engl); 2024 Feb; 137(3):338-349. PubMed ID: 38105538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.